Basic Information | Post buying leads | Suppliers | Cas Database |
The Etizolam, with the CAS registry number 40054-69-1, has the systematic name of 4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine. Etizolam is a thienodiazepine drug which is a benzodiazepine analog. The etizolam molecule differs from a benzodiazepine in that the benzene ring has been replaced by a thiophene ring. It possesses amnesic, anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant properties.
The physical properties of Etizolam are as followings:
(1)ACD/LogP: 2.2; (2)ACD/LogD (pH 5.5): 2.20; (3)ACD/LogD (pH 7.4): 2.20; (4)ACD/BCF (pH 5.5): 27.61; (5)ACD/BCF (pH 7.4): 27.67; (6)ACD/KOC (pH 5.5): 374.07; (7)ACD/KOC (pH 7.4): 374.76; (8)#H bond acceptors: 4; (9)#Freely Rotating Bonds: 2; (10)Index of Refraction: 1.734; (11)Molar Refractivity: 95.855 cm3; (12)Molar Volume: 239.206 cm3; (13)Polarizability: 38 10-24cm3; (14)Surface Tension: 53.9410018920898; (15)dyne/cm Density: 1.433 g/cm3; (16)Flash Point: 283.561 °C; (17)Enthalpy of Vaporization: 82.406 kJ/mol; (18)Boiling Point: 545.256 °C at 760 mmHg; (19)Vapour Pressure: 0 mmHg at 25°C.
Uses of Etizolam:
Etizolam is a thienodiazepine-based drug with multiple therapeutic properties that is sometimes used to treat anxiety, panic disorder, depression, or sleep disorders. At least one clinical trial has found etizolam to be more effective than a placebo in alleviating symptoms of depression and generalized anxiety disorder. This medication's effects are similar to those of the benzodiazepine drug family that includes lorazepam, clonazepam, and triazolam.
You can still convert the following datas into molecular structure:
(1)SMILES: Clc1ccccc1/C4=N/Cc2nnc(n2c3sc(cc34)CC)C;
(2)InChI: InChI=1/C17H15ClN4S/c1-3-11-8-13-16(12-6-4-5-7-14(12)18)19-9-15-21-20-10(2)22(15)17(13)23-11/h4-8H,3,9H2,1-2H3;
(3)InChIKey: VMZUTJCNQWMAGF-UHFFFAOYAX;
The toxicity data of Etizolam is as follows:
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
mouse | LD50 | intraperitoneal | 783mg/kg (783mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION | Oyo Yakuri. Pharmacometrics. Vol. 16, Pg. 1021, 1978. |
mouse | LD50 | oral | 3070mg/kg (3070mg/kg) | United States Patent Document. Vol. #4094984, | |
mouse | LDLo | subcutaneous | 5gm/kg (5000mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION | Oyo Yakuri. Pharmacometrics. Vol. 16, Pg. 1021, 1978. |
rat | LD | intravenous | > 5gm/kg (5000mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION | Oyo Yakuri. Pharmacometrics. Vol. 16, Pg. 1021, 1978. |
rat | LD50 | intraperitoneal | 825mg/kg (825mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION | Oyo Yakuri. Pharmacometrics. Vol. 16, Pg. 1021, 1978. |
rat | LD50 | oral | 3509mg/kg (3509mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION | Oyo Yakuri. Pharmacometrics. Vol. 16, Pg. 1021, 1978. |
rat | LD50 | subcutaneous | > 5gm/kg (5000mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 28, Pg. 1158, 1978. |